WATERTOWN, Mass.--(BUSINESS WIRE)--Selecta Biosciences, Inc., a clinical stage biotechnology company developing a novel class of targeted antigen-specific immune therapies using Synthetic Vaccine Particles (SVP), today announced the appointment of Earl (‘Skip’) Sands, MD, as Chief Medical Officer (CMO). As CMO, Dr. Sands will oversee all clinical development and regulatory activities for the company, as Selecta rapidly advances its product candidates in and toward human clinical trials for a range of diseases, including refractory gout, gene therapy, smoking cessation, human papillomavirus (HPV) associated cancers, and others.
Help employers find you! Check out all the jobs and post your resume.
